Note 2022 $’000 2021 $’000 Revenue from contracts with customers 4 14,553 – Other income 4 2,480 3,636 Total income 17,033 3,636 Research and development costs (12,712) (9,516) Corporate and administrative costs (3,437) (1,914) Loss on financial derivatives measured at fair value through profit or loss (700) – Profit/(loss) before income tax 184 (7,794) Income tax 6 – – Profit/(loss) after income tax 184 (7,794) Other comprehensive income, net of tax Amounts which may be subsequently reclassified to profit or loss: Exchange differences on translation of foreign operations 2 (4) Total comprehensive income/(loss) for the year 186 (7,798) Profit/(loss) after tax attributable to Equity holders of the Company: 184 (7,794) Total comprehensive income/(loss) attributable to Equity holders of the Company: 186 (7,798) Basic earnings/(loss) per share 7 $0.001 ($0.066) Diluted earnings/(loss) per share 7 $0.001 ($0.066) The notes on pages 30 to 44 form part of these consolidated financial statements. CONSOL I DATED STATEMENT OF COMPREHENS I V E I NCOME FOR T H E Y E A R E ND E D 3 1 D E C EMB E R 2 0 2 2 Neuren Pharmaceuticals Limited Annual Repor t 2022 26
RkJQdWJsaXNoZXIy MjE2NDg3